Floatz logo

TIL

Peritoneal Cancer

Inge Marie SvaneCell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Rucaparib
pharmaand GmbH
Phase 3BB

View all 50 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →